NanoVibronix's UroShield Completes Pilot Phase for UTI Prevention
• NanoVibronix has successfully completed the pilot phase of a randomized controlled trial for UroShield, a device designed to prevent catheter-associated urinary tract infections (UTIs). • The pilot phase, conducted at the University of Michigan, focused on refining recruitment strategies and assessing data collection tools for the full study. • The upcoming full study will enroll approximately 300 participants and will run concurrently with preparations for UroShield's potential US market launch, pending FDA 510K clearance. • UroShield utilizes low-intensity ultrasonic waves to prevent bacterial colonization on urinary catheters, potentially reducing UTIs and improving patient quality of life.

Stay Updated with Our Daily Newsletter
Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.
Related Topics
Reference News
NanoVibronix, Inc. announced the successful completion of the first phase of a Randomized Control Trial for UroShield®, ...
NanoVibronix completed the pilot phase of a trial for UroShield, a device preventing catheter-associated infections, wit...